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Abstract
X-ray diffraction studies reveal the structure of {[(2-CsH5-1,2-C2BloHlo-I-COO)Bu2Sn]20}2, 1, to
conform to the common motif found for {[(R’COO)R2Sn]20}2 compounds. The dimer features a
central Bu4Sn202 unit (two-fold symmetry) with the two Bu2Sn groups being linked via bridging
oxygen atoms, each of which also carries an exocyclic Bu2Sn moiety. The two pairs of exo- and
endo-cyclic tin atoms are each linked via an almost symmetrically bridging carboxylate ligand and the
two remaining ligands coordinate an exocyclic tin atom only, in the monodentate mode. The in vitro
anti-tumour activity of 1, determined against a variety of cell lines, is compared with those of the
corresponding 2-methylcarboranylacetate, derivative 2, and with clinically used compounds.
1. Introduction
The in vitro anti-tumour activity of many compounds of the type {[(R’COO)Bu2Sn]20}2 has
been determined [1-4]. Generally, the compounds are quite active. The synthesis and X-ray crystal
structure of the dimeric bis-[(1,7-dicarba-c/oso-dodecaborane-l-carboxylato)-di-n-butyltin] oxide,
{[(1,7-C2B10H11-1-COO)Bu2Sn]20}2, has already been reported [5]. Its in vitro anti-tumour activity is
less than those of several compounds of the type {[(R’COO)Bu2Sn]20}2, comparable to those of
methotrexate and doxorubicin, but greater than those of 5-fluorouracil, cis-platin and carboplatin [5].
As a continuation of studies on organotin carboxylates, the synthesis, spectral characterisation, and
in vitro anti-tumour activity of a bis-[(2-phenyl-1,2-carborane-l-carboxylato)di-n-butyltin] oxide, {[(2-
C6H5-1,2-C2BloHlo-I-COO)Bu2Sn]20}2 (1), and of bis[1-(2-methyl-1,2-carboranyl)-l-acetato-di-n-
butyltin] oxide, {[(2-CH3-1,2-C2B10H10-1-CH2-COO)Bu2Sn]20}2 (2), are reported together with the X-
ray structure of 1.
2. Results and Discussion
2.1. Synthesis
The novel dimeric bis[(2-phenyl-l,2-dicarba-closo-dodecaborane-l-carboxylato)-di-n-
butyltin] oxide, compound 1, was obtained from a 1:1 condensation of dibutyltin(IV) oxide with 2-
phenyl-1,2-carborane-l-carboxylic acid. Its structure was determined by spectroscopic and X-ray
diffraction methods. The 1-(2-methyl-l,2-carboranyl)acetate derivative, 2, was synthesised using
an analogous procedure. The 1H, 13C and 117Sn NMR spectra of the compounds display the usual
duplicate resonances arising from the two heterotopic pairs of. Bu2Sn moieties of dim’eric
dicarboxylatotetraorganodistannoxanes, {[(R’COO)R2Sn]20}2 [1-5].
2.2. Crystal and molecular structure of {[(2-C6H5-1,2-C2B10H o" 1-CO0)Bu2Sn]20}2, 1
The molecular structure of 1 is illustrated in Figure and selected interatomic parameters
are collected in Table 1. The analysis shows that the structure is similar to those of a majority [6] of
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analogous {[(R’COO)R2Sn]20}2 compounds that usually feature a centrosymmetric Sn202 core
(containing the endocyclic tin atoms) which associate, via the oxygen atom, to two exocyclic tin
atoms leading to a partial ladder arrangement. The {[(R’COO)R2Sn]20}2 motifs differ in the mode of
association of the four carboxylate ligands to the Sn402 moiety [6].




Compound 1 Z= R Ph
Compound 2 Z CH2 R Me
The predominant motif shows two of the carboxylates to be bidentate, bridging a pair of endo- and
exocyclic tin atoms, and each of the other two carboxylates to coordinate an exocyclic tin atom
























Figure 1: Molecular structure and crystallographic numbering scheme for [(2-C6H5-1,2-C2B 10HI0-1-
COO)Bu2Sn]20 }2. Hydrogen atoms are omitted for clarity. For the carboxylate moieties with C(1), the B(3)
atom is obscured under C(31) and B(7) occupies a position in the B(5)-B(9) pentagonal plane. For the second
carboxylate, B(12) lies above B(19) in the middle of the carborane as viewed.
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This mode of coordination results in two five-coordinate, trigonal bipyramidal tin atom
geometries. The structure of 1 is different from most of the other structures in that there is
crystallographic two-fold symmetry, rather than a centre of inversion. It is noted that the core, mode
of association of the carboxylate ligands and coordination geometries are as found for the common
motif.
The structure of 1 is essentially molecular with no non-hydrogen contacts less than 3.6/.
Within the molecule, one carboxylate ligand, i.e. containinC(1), bridges the Sn(1) and Sn(2) atoms
forming almost symmetric Sn-O distances of 2.314(4) A and 2.276(4)/,, respectively, and the
second independent carboxylate anion forms a monodentate contact with Sn(2) such that Sn-O(4)
is 2.244(4) A. The Sn(1) atom lies 0.1335(4) , out of the trigonal plane defined by the O(1), C(61)
and C(71) atoms in the direction of the O(1)’ atom, and Sn(2) lies 0.0315(4)/ out of the O(1), C(81)
and C(91) plane towards the 0(4) atom. The O(2)-Sn(1)-O(1)’ and O(3)-Sn(2)-O(4) axial angles of
167.8(1) and 169.7(2), respectively represent only small deviations from the ideal. Deviations from
the ideal angles in the trigonal plane may be traced to close Sn...O intramolecular contacts. Thus,
the 0(4)’ atom is separated by 2.734(4) , from the Sn(1) centre and the Sn(2)...O(5) contact is
2.916(4)/,. These interactions are too long to represent significant bonding contacts; however,
they are at least partly responsible for the widening of the C-Sn-C angles to 147.3(2) and 141.6(3),
respectively. If the Sn(1)-O(4)’ interactions were considered significant, the molecular geometry
may be described as being based on a Sn404 ladder, however, the relatively weak nature of these
interactions suggests that a better description would be one based on a partially completed ladder.
TABLE 1. Selected interatomic parameters (/,, deg.) for 1. Primed atoms are related by a crystallographic
two-fold axis
Sn(1)-O(1) 2.062(4) Sn(1)-O(1)’ 2.160(4)
Sn(1)-O(2) 2.314(4) Sn(1 )-C(61) 2.127(7)
Sn(1)-C(71) 2.128(6) Sn(2)-O(1) 2.029(3)
Sn(2)-O(3) 2.276(4) Sn(2)-O(4) 2.244(4)
Sn(2)-C(81) 2.115(7) Sn(2)-C(91) 2.144(7)
O(2)-C(1) 1.222(7) O(3)-C(1) 1.245(8)
O(4)-C(4) 1.298(7) O(5)-C(4) 1.204(8)
C(1 )-C(2) 1.525(8) C(4)-C(5) 1.534(9)
O(1)-Sn(1)-O(1)’ 77.2(1) O(1)-Sn(1)-O(2) 90.6(1)
O(1)-Sn(1)-C(61) 106.3(2) O(1)-Sn(1)-C(71) 105.1(2)
O(1)’-Sn(1)-O(2) 167.8(1) O(1)’-Sn(1)-C(61) 98.4(2)
O(1 )-Sn(1 )-C(71) 97.5(2) O(2)-Sn(1)-C(61) 84.7(2)
O(2)-Sn(1)-C(71) 85.7(2) C(61)-Sn(1)-C(71) 147.3(2)
O(1)-Sn(2)-O(3) 90.6(1) O(1)-Sn(2)-O(4) 80.1(1)
O(1)-Sn(2)-C(81) 109.0(2) O(1)-Sn(2)-C(91) 109.3(2)
O(3)-Sn(2)-O(4) 169.7(2) O(3)-Sn(2)-C(81) 86.5(2)
O(3)-Sn(2)-C(91) 90.8(2) O(4)-Sn(2)-C(81) 92.4(2)
O(4)-Sn(2)-C(91) 96.3(2) C(81)-Sn(2)-C(91) 141.6(3)
Sn(1)-O(1)-Sn(1)’ 102.8(1) Sn(1)-O(1)-Sn(2) 137.5(2)
Sn(1)-O(1)’-Sn(2)’ 119.7(2) Sn(1)-O(2)-C(1) 134.7(4)
Sn(2)-O(3)-C(1) 137.4(4) Sn(2)-O(4)-C(4) 107.9(4)
O(2)-C(1 )-O(3) 127.3(6) O(2)-C(1 )-C(2) 118.0(6)
O(3)-C(1)-C(2) 114.7(5) O(4)-C(4)-O(5) 125.0(6)
O(4)-C(4)-C(5) 114.7(5) O(5)-C(4)-C(5) 120.3(5)
A partial crystal structure of 2 was obtained (see Experimental). The refinement halted at R
ca 13 % and hence, the derived parameters are not reliable. The gross structural features were
determined unambiguously, however, and showed that the common (i.e. centrosymmetric) motif
found for {[(R’COO)R2Sn]20}2 is adopted by 2 [6].
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The compounds {[(2-C6H5-1,2-C2BloH10-1-COO)Bu2Sn]20}2, 1, and {[(2-CH3-1,2-C2BloHlo-
1-CH2-COO)Bu2Sn]20}2, 2, were screened in vitro against seven tumoural cell lines of human
origin. The ID50 values obtained, in ng/mL, are summarised in Table 2.
Against these cell lines, compounds 1 and 2 are significantly more active than 5-
fluorouracil, cis-platin and carboplatin but less active than methotrexate and doxorubicin, whereas
the parent carboxylic acid of 1 is inactive. The results for 1 and 2 are similar to those reported earlier
for {[(1,7-C2B10H11-1-COO)Bu2Sn]20}2 [5] and show that these carborane derivatives possess
medium activity.
3. Experimental
3.1. Synthesis and purification
2-Phenyl-l,2-carborane-l-carboxylic acid, compound 3, was prepared following Zakharkin
et al. [7a] by the action of an equimolar amount of n-butyl lithium to 1-phenyl-1,2-carborane followed
by the carboxylation of the obtained 2-phenyl-l-lithio-1,2-carborane with CO2 and acid hydrolysis.
(2-Methyl-1,2-carboran-l-yl)acetic acid, compound 4, was also prepared following Zakharkin et al.
[7b] by the action of equimolar amount of magnesium on 2-methyl-l-chloromethyl-l,2-carborane
followed by carboxylation with CO2 of the Grignard reagent obtained, followed by acid hydrolysis.
Compound 1 was synthesised in benzene (150 mL) from di-n-butyltin oxide (664 mg) and 3 (500
mg). After 20 minutes of reflux, the clear solution obtained was refluxed for a further 5 h. The
binary water/benzene azeotrope was distilled off with a Dean-Stark funnel. The benzenic solution
obtained was distilled to 50% of its initial volume and the remaining solvent was evaporated in
vacuo. The solid obtained, compound 1, was purified by recrystallisation from methylene
chloride/n-hexane. Yield: 76%, m.p.: 144-147 ooC Compound 2 was synthesised similarly using 4.
Yield: 78%, m.p.: 185-188 ooC.
TABLE 2. In ,vitro anti-tumour activities (ng/mL) of bis-[2-phenyl-l,2-dicarba-closo-dodecaborane-l-
carboxylato)-tetra-n-butyltin] oxide, compound 1, of the parent carboxylic acid, 1-phenyl-l,2-carborane-1-
carboxylic acid, compound 3, of bis-[ 1-(2-methyl-1,2-dicarba-closo-dodecaboranylacetato)-tetra-n-butyltin]
oxide, compound 2, and of some reference compounds used clinically, against MCF-7 and EVSA-T, two
breast cancers, WiDr, a colon cancer, IGROV, an ovarian cancer, M19 MEL, a melanoma, A498, a renal
cancer and H226, a non small cell lung cancer.
Compounds MCF-7 EVSA-T WiDr IGROV M19 MEL A498 H226
1 138 164 514 169 220 301 388
2 74 140 283 102 172 182 246
3 56500 1750 45100 42400 58300 >60000 55000
Carboplatin 10500 4500 3500 2400 5500 1800 25000
Cis-platin 1400 920 1550 230 780 1200 3158
5-Fluorouracil 350 720 440 850 31 0 340 5300
Doxorubicin 25 3 8 150 21 55 80
Methotrexate 5 26 7 20 8 6 70
3.2. Structure determination of {[(2-C6H5-1,2-C2B1oH1o-1-CO0)Bu2Sn]20}2, 1
Intensity data for a colourless crystal (0.10 x 0.26 x 0.39 mm) were measured at room
temperature on a Rigaku AFC6R diffractometer fitted with MoKo radiation (graphite monochromator,
X 0.71073 A) using the e:2e scan technique so that emax was 27.5. No decomposition of the
crystal occurred during the data collection and the data set was corrected for Lorentz and
polarization effects [8], and for absorption employing an empirical procedure (range of transmission
factors: 0.942 1) [9]. A total of 12166 data (11932 unique) were collected and of these, 5729 that
satisfied the > 3.0(/) criterion were used in the subsequent analysis.
78EdwardR. T. TieMnk, Marcel Gielen et aL Metal-Based Drugs
Cr/stal data for 1. 068H132B40010Sn4, M 2016.9, monoclinic, space group C2/c, a
28.877(6) A, b= 14.818(2) A, c= 23.275(2) A, I 92.26(1), V= 9951(2) A3, Z= 4, Dexpt- 1.346 g
cm-3, F(000) 4080, 10.41 cm-1.
The structure was solved by direct methods [10] and refined by a full-matrix least-squares
procedure based on F [8]. The non-hydrogen atoms were refined with anisotropic displacement
.arameters
and hydrogen atoms were included in the model in their calculated positions (C-H 0.97
with the exception for the C(91-94) butyl group. This latter group was found to have high thermal
motion/disorder such that the C(92) atom was located over two positions of equal weight; hydrogen
atoms were not included. The refinement was continued until convergence with sigma weights
when R 0.038 and Rw 0.044. The maximum residual in the final difference map was 0.49 e A-3.
The numbering scheme employed is shown in Fig. which was drawn with ORTEP [11] at 35 %
probability ellipsoids. Data manipulation were performed with the teXsan program [8] installed on an
Iris Indigo work station. Other crystallographic details, comprising fractional atomic coordinates,
thermal parameters, all bond distances and angles (in ClF format), and tables of observed and
calculated structure factors are available on request (ERTT).
A partial structure of 2 was obtained. Data collection was as for 1. Some butyl carbon atoms
could not be located and the refinement was stopped at R 0.133, Rw 0.162.
Crystal data for 2.052H132B4001o0Sn4, M 1824.8 monoclinic,_ space group P2/c, a
16.36(1) A, b 19.819(5) .&., c 14.69(2) A, I 106.86(8), {/= 4558(6) A3, Z= 2, Dexpt- 1.329 g
cm-3, F(000)= 1848, 11.28 cm"
3.3. NMR experiments
All NMR spectra were recorded in CDCI3 solutions on a Bruker AC250 instrument, using a
QNP probe tuned at 250.13, 62.93, and89.128 MHz for 1H, 13C, and 117Sn nuclei, respectively. 1H
and 13C resonances were referenced to the solvent peak at 7.24 and 77.0 ppm, while ,(117Sn)
35.632295 [12] was used for the 117Sn resonances. Chemical shifts in ppm and coupling constants
in Hz. Abbreviations: triplet; tq triplet of quartet; m complex pattern; nv non visible.
3.4. M(ssbauer spectra
MSssbauer spectra were obtained as described previously [13]. QS quadrupole splitting;
IS isomer shift; ]-’1 and ]"2 line widths, all in mm/s.
3.5. Characterization
Compound 1:
Mossbauer: QS: 3.72, IS: 1.44, ]"1: 0.99; ]"2: 1.03; 1H NMR: o-, 13- and y-CH2: 1.05-1.15, m; CH3: 3 7 0.83 (t, 7) & 0.86 ppm (t, 7); Ho: 7.59-7.62, m; Hm+: 7.24-7.46, m; C NMR: C-1 & C-2:9.6 &
83.3; CO: 163.6; Ci: 131.7; Co: 131.1; Cm: 128.4; #: 130.4; Co: 28.8 [1j(13C-119/117Sn): 677] &
13 119/117 2 13 119/117 2 13 119/117 n nv 26 8 30.4[ J( C- Sn): 710]; Cl: 26.5 J( C- n): 40] & 26.8[ J( C- S ): ]; C_:
[3j(13C-119/117Sn): 127] & 27.4 [3j(13C-119/117Sn): 132]; CH3:13.57 & 13.63 ppm; 117Sn NMR:
-201.6 [2j(119Sn.O.119/117Sn): 131 & -189.3 ppm [2j(119Sn.O.119/117Sn): 125].
Compound 2:
MSssbauer: QS: 3.53, IS: 1.36, [’1: 0.83; ]"2: 0.83; 1H NMR: (z-CH2: 1.59-1.65, I- and y-CH2: 1.31-
1.46, m; CH3:0.91 (t, 7) & 0.93 ppm (t, 7); C-CH2:3.06 (s); C-CH3:2.07 (s); 3C NMR: C-1 & C-2:
74.8 & 72.9; CO: 172.3; C-CH: 43.2; C-CH3: 23.5; Co: 27.7 [1j(13C-119/117Sn): 670] & 30.9 [1j(13C-
119/117Sn nv 2 7 2 13 119/117 2 13 119/117 n 4 C 267 3j(13C ): ];CI: 6. [J( C- Sn):42]&26.8[ J( C- S ): 3];
119/117 3 13 119/117 117 2 119 n Sn): 125] & 27.3 J( C- Sn): 120]; CH3:13.5 & 13.6 ppm; Sn NMR:-05.2 J( S
119/117 1 2 2 1 m 2 119Sn O 119/117Sn 116 O- Sn): 2 ]&- 0 .0pp [J( ): ].
3.6. In vitro screening
The in vitro tests were performed as described previously [14].
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